Lower mean platelet volume is a risk indicator of hepatocellular carcinoma recurrence following liver transplantation

被引:11
|
作者
Zhang, Ai-Bin [1 ]
Zhang, Zhi-Hao [2 ]
Zhang, Jie [3 ]
Lin, Bing-Yi [1 ,2 ]
Geng, Lei [1 ,2 ]
Yang, Zhe [1 ,2 ]
Feng, Xiao-Ning [1 ]
Zheng, Shu-Sen [1 ,2 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Surg, Div Hepatobiliary & Pancreat Surg,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Key Lab Combined Multiorgan Transplantat, Minist Publ Hlth,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
[3] Jiaxing Univ, Hosp Jiaxing 1, Dept Hepatobiliary Surg, Jiaxing 314000, Peoples R China
关键词
Hepatocellular carcinoma; Mean platelet volume; Liver transplantation; Platelet; Prognosis; ABSOLUTE MONOCYTE COUNT; C-REACTIVE PROTEIN; CANCER-CELLS; PROGNOSIS; DIAGNOSIS;
D O I
10.1016/j.hbpd.2019.04.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Lower mean platelet volume (MPV) is an indicator of platelet activity in the setting of tumor development. This study was to assess the relationship between preoperative MPV and survival outcomes of patients with hepatocellular carcinoma (HCC) following liver transplantation (LT). Methods: The demographic and clinical characteristics of 304 HCC patients following LT were retrieved from an LT database. All the patients were divided into the normal and lower MPV groups according to the median MPV. The factors were first analyzed using a Kaplan-Meier survival analysis, then the factors with P < 0.10 were selected for multivariate Cox regression analysis and were used to define the independent risk factors for poor prognosis. Results: The 1-, 3-, and 5-year tumor free survival was 95.34%, 74.67% and 69.29% in the normal MPV group, respectively, and 95.40%, 59.97% and 42.94% in the lower MPV group, respectively (P < 0.01). No significant difference was observed in post-LT complications between the normal and lower MPV groups. Portal vein tumor thrombosis (PVTT) [hazard ratio (HR =2.24; 95% confidence interval: 1.46-3.43; P < 0.01) and lower MPV (HR =1.58; 95% confidence interval: 1.05-2.36; P=0.03) were identified as independent prognostic risk factors for recipient survival. Conclusion: Preoperative lower MPV is a risk indicator of HCC patients survival outcomes after LT. (C) 2019 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 50 条
  • [21] Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation
    Citores, Maria J.
    Lucena, Jose L.
    de la Fuente, Sara
    Cuervas-Mons, Valentin
    WORLD JOURNAL OF HEPATOLOGY, 2019, 11 (01) : 50 - 64
  • [22] Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation
    Orci, L. A.
    Berney, T.
    Majno, P. E.
    Lacotte, S.
    Oldani, G.
    Morel, P.
    Mentha, G.
    Toso, C.
    BRITISH JOURNAL OF SURGERY, 2015, 102 (10) : 1250 - 1257
  • [23] DONOR CHARACTERISTICS AND THE RISK OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION
    Orci, L. A.
    Combescure, C.
    Majno, P. E.
    Berney, T.
    Oldani, G.
    Morel, P.
    Mentha, G.
    Toso, C.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S54 - S54
  • [24] Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation
    De Simone, Paolo
    Precisi, Arianna
    Lai, Quirino
    Ducci, Juri
    Campani, Daniela
    Marchetti, Piero
    Gitto, Stefano
    CANCERS, 2024, 16 (07)
  • [25] PREDICTIVE RISK FACTORS OF RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
    Gentili, F.
    Lai, Q.
    Giusto, M.
    Mennini, G.
    Berloco, P. B.
    Rossi, M.
    De Santis, A.
    Corradini, S. Ginanni
    Attili, A. F.
    Merli, M.
    DIGESTIVE AND LIVER DISEASE, 2009, 41 (05) : A16 - A16
  • [26] Donor characteristics and the risk of hepatocellular carcinoma recurrence after liver transplantation
    Orci, L. A.
    Berney, T.
    Majno, P. E.
    Lacotte, S.
    Oldani, G.
    Morel, P.
    Mentha, G.
    Toso, C.
    BRITISH JOURNAL OF SURGERY, 2014, 101 : 1 - 1
  • [27] Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation
    Maria J Citores
    Jose L Lucena
    Sara de la Fuente
    Valentin Cuervas-Mons
    World Journal of Hepatology, 2019, 11 (01) : 50 - 64
  • [28] Hepatocellular Carcinoma Recurrence is an independent Risk Factor for HB Recurrence After Liver Transplantation
    Gao, Peng-ji
    Gao, Jie
    Li, Zhao
    Hu, Zhi-ping
    Zhu, Ji-ye
    HEPATO-GASTROENTEROLOGY, 2014, 61 (134) : 1523 - 1528
  • [29] Clinically Evident Portal Hypertension Is an Independent Risk Factor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation
    Kornberg, Arno
    Seyfried, Nick
    Friess, Helmut
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (06)
  • [30] Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation
    Han, Sangbin
    Lee, Sanghoon
    Yang, Ju Dong
    Leise, Michael Douglas
    Ahn, Joong Hyun
    Kim, Seonwoo
    Jung, Kangha
    Gwak, Mi Sook
    Kim, Gaab Soo
    Ko, Justin Sangwook
    LIVER TRANSPLANTATION, 2018, 24 (01) : 44 - 55